Outset Medical (OM) Q2 2026 earnings review
Margins Expand and Cash Burn Drops, But Core Growth is Sputtering
Outset Medical snapped its streak of sequential top-line declines, posting $31.6M in Q2 revenue (+14% QoQ, +1% YoY). The real story, however, is a tale of two income statements. Operationally, the company is executing well: gross margin hit 42.0% (up 420 bps YoY) and cash burn slowed to just $9.5M for the quarter. The landmark $40M HCA Healthcare refresh agreement secures valuable backlog. Yet, the underlying growth metrics are deeply concerning. Product revenue fell 5% YoY, and the supposedly sticky recurring revenue actually shrank to $22.1M. Management's reiterated $125-$130M full-year guide implies a heroic acceleration in the back half of the year.
🐂 Bull Case
The 3-year, $40M agreement with HCA Healthcare to refresh its Tablo fleet is a massive vote of confidence from the nation's largest health system, locking in future revenue and providing a blueprint for other enterprise accounts.
With gross margins clearing 42% and quarterly cash burn dropping to $9.5M, Outset's $151M liquidity pool provides ample runway. The threat of imminent dilution has significantly diminished.
🐻 Bear Case
Despite management claiming the 'highest number of successful new site installations in several years,' recurring revenue actually declined YoY to $22.1M from $22.5M. This signals lower utilization per console or intense pricing pressure.
Consoles are supposed to be the tip of the spear, but product revenue decelerated sharply, falling 5% YoY to $21.9M. Without new placements, the long-term consumable tailwind dies.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for stopping the bleeding on cash and margins. The HCA deal is a major win. However, negative product growth and shrinking recurring revenue make the reiterated full-year guidance look highly optimistic.
Key Themes
Landmark HCA Refresh Agreement
Outset signed a 3-year, $40M agreement with HCA Healthcare to refresh its existing fleet. This is critical for two reasons: it secures visible backlog in an otherwise lumpy capital equipment environment, and it proves that early enterprise adopters are willing to double down on the Tablo ecosystem rather than reverting to traditional providers.
Service Margin Explosion
The primary engine behind the company's gross margin expansion isn't hardware—it's service. Service and other gross margin skyrocketed to 32.6% from 6.9% a year ago. This accelerating profitability in the service division more than offset a 280 bps drop in product gross margin (from 48.9% to 46.1%).
Next-Generation Tablo Launch Catalyst
The company's 'Next-Generation Tablo' platform remains a vital upcoming catalyst. Positioned as the first dialysis system cleared under the FDA's strict 2025 cybersecurity requirements, management is aggressively using this as a competitive wedge to force health systems into refresh cycles.
Contradictory Recurring Revenue Data
Management touted the 'highest number of successful new site installations in several years.' Yet, recurring revenue from consumables and service fell to $22.1M, down from $22.5M in the prior-year period. This data point completely contradicts the positive narrative. It implies that while new sites are opening, overall utilization across the broader installed base is dropping, or the company is conceding on price.
Capital Equipment Macro Squeeze
Outset is fundamentally a capital equipment business selling into hospital systems. Product revenue reversed from historical growth into a 5% YoY contraction ($21.9M vs $23.1M). The macroeconomic reality of constrained hospital capital budgets continues to stretch out sales cycles and delay enterprise closures.
Heroic Second-Half Implied Ramp
By reiterating the $125M-$130M full-year revenue guide, management has painted themselves into a corner. With $59.5M generated in H1, Outset needs to print between $65.5M and $70.5M in H2. This implies accelerating H2 YoY growth to roughly 12-20%, which contradicts the flat/negative growth seen in H1.
Other KPIs
Accelerating improvement. Cash burn is stabilizing dramatically. The company used only $9.5M in the quarter and $22.5M for the first six months of 2026. This is a massive structural improvement compared to prior years where annual cash burn exceeded $100M. With $151M in total liquidity, Outset has successfully defused immediate balance sheet risk.
Stable. Excluding stock-based compensation and $0.6M in litigation charges, operating expenses were roughly flat YoY. General & Administrative expenses rose to $11.4M (GAAP) from $9.2M, primarily due to non-routine litigation costs related to ongoing stockholder lawsuits.
Guidance
Accelerating significantly into H2. Management reiterated this target, which implies 5% to 9% growth over FY25's $119.5M. Given the +1% growth in Q2 and -6% in Q1, achieving this requires a massive inflection in enterprise deal closures and new product adoption in Q3 and Q4.
Stable. Having posted 43.8% in Q1 and 42.2% in Q2, this guidance is easily achievable and simply requires maintaining the current cost-control run rate.
Key Questions
Recurring Revenue Disconnect
You noted the highest number of new site installations in several years, yet recurring consumable and service revenue declined slightly YoY to $22.1 million. Is this a pricing dynamic, an inventory destocking issue at the hospital level, or are overall utilization rates per console declining?
HCA Deal Phasing
Regarding the $40M HCA refresh agreement over three years, how back-end or front-end loaded is this contract, and how much of this revenue is factored into the implied steep H2 2026 ramp?
Bridge to H2 Guidance
To hit the midpoint of your $125M-$130M revenue guidance, you need to average roughly $34M per quarter in the back half. Given product revenue contracted 5% this quarter, what specific near-term catalysts give you confidence in this sharp acceleration?